IST confident on licensing deal as multiple myeloma antibody moves forward
This article was originally published in Scrip
Executive Summary
Immune System Therapeutics (IST) expects to conclude a partnering deal for its lead development project by the end of the year, a move that would boost the Australian biotech's prospects for the Phase III development and commercialisation of the multiple myeloma (MM) therapy.